Received Jun 1, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPAB | HEP A + HEP B (TWINRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | F95HB | — |
Late second dose/ first dose was administered two years ago January twenty sixth twenty twenty-three, second dose was administered on May twenty fifth twenty twenty-six; This non-serious case was reported by a other health professional via call center representative and described the occurrence of drug dose administration interval too long in a 66-year-old female patient who received HAB (Twinrix) suspension for injection in pre-filled syringe (batch number F95HB with expiry date 29-MAY-2028) for prophylaxis. Previously administered products included Twinrix (received first dose on 26-JAN-2023). On 25-MAY-2026, the patient received the 2nd dose of Twinrix. On 25-MAY-2026, an unknown time after receiving Twinrix, the patient experienced drug dose administration interval too long (Verbatim: Late second dose/ first dose was administered two years ago January twenty sixth twenty twenty-three, second dose was administered on May twenty fifth twenty twenty-six). The outcome of the drug dose administration interval too long was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 28-MAY-2026 The healthcare provider called to ask about a patient's vaccination schedule because they were off schedule. The reporter wanted to know when this patient could be administered with the third dose. The vaccine administration facility was the same as primary reporter. The batch number was not provided upon follow up with the reporter.